June 3 (Reuters) - Beigene Ltd:
* BEIGENE ANNOUNCES THE APPROVAL OF BRUKINSA™ (ZANUBRUTINIB) IN CHINA FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AND RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
* BEIGENE LTD - RECOMMENDED DOSE OF BRUKINSA IN CHINESE PACKAGE INSERT IS 160 MG TWICE DAILY TAKEN ORALLY WITH OR WITHOUT FOOD Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.